Tempus AI Scoops Up Genomics Play For $1.5 Billion; But S…

Tempus AI has announced its intention to acquire cancer diagnostics company Personalis for $1.5 billion. This acquisition, with a share valuation of $16.25—approximately a 6% premium to Friday's closing price and 28% over the 30-day price—aims to enhance innovation and value for patients and partners. Despite the strategic benefits, the stocks of both companies experienced significant declines following the announcement. Financial analysts view the high valuation and growth potential of Personalis as justified, particularly due to its NeXT Personal test for cancer detection. The deal is expected to finalize in late 2026 or early 2027, contingent upon regulatory and competitive considerations.

Store

SubscribeSign In

My Subscriptions

Customer Center My Stock Lists Email Preferences Help & Support Sign Out

Search stocks or keywords

Sections

My IBD

Market Trend

MARKET TREND

The Big Picture Stock Market Today ETF Market Strategy Stock Market Data Psychological Indicators New? Start Here IBD Digital: 2 Months for $20

Stock Lists

STOCK LISTS

IBD 50 IBD Sector Leaders IBD Big Cap 20 IBD Long-Term Leaders IPO Leaders My Stock Lists Stock Lists Update Stocks On The Move New Highs Stock Spotlight Stocks Near Buy Zone RS Line At New High Rising Profit Estimates Stocks Funds Are Buying Your Weekly Review Breakout Stocks Index IBD ETF Indexes IBD Data Tables IBD Digital: 2 Months for $20 New? Start Here

Research

STOCK RESEARCH

IBD Stock Checkup Stock Of The Day Screen Of The Day IBD Charts Stock Screener Swing Trading Options Investing Action Plan Earnings Preview Earnings Calendar IBD Industry Themes The New America Best ETFs Best Mutual Funds The Income Investor IBD Stock Analysis Industry Snapshot IBD 50 Stocks To Watch IBD Data Stories IBD Digital: 2 Months for $20

News

NEWS

eIBD Technology Magnificent Seven Stocks Personal Finance Special Reports Cryptocurrency Retirement Management

ECONOMY

Economic Calendar Economic News IBD Digital: 2 Months for $20

Videos

VIDEOS & PODCASTS

IBD Live How To Invest Videos Options Videos Investing With IBD Podcast Growth Stories Podcast Webinars Online Courses IBD Digital: 2 Months for $20

Learn

HOW TO INVEST

How To Invest In Stocks Stock Investing Keys Stock Market Timing Track Market Trends How To Read Stock Charts How To Buy Stocks When To Sell Stocks Short Selling Swing Trading What Is Crypto

EDUCATIONAL RESOURCES

New to IBD Investor's Corner Investing With IBD Podcast Events & Webinars IBD Moneyworks 12 Days Of Learning Investing Infographics Premium Online Courses Premium Workshops

Store

My Products

Founder's Club SwingTrader Leaderboard MarketSurge eIBD IBD Digital IBD Live

Recently Searched

Investing Action Plan 7/18/2026

Stock Market Week Ahead: Navigating Uncertainty

Research 7/18/2026

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Google Holds Top Rating

News 7/18/2026

ASML, Snowflake Lead Five Stocks Near Buy Points In Tough Market

Tempus AI ( TEM) pledged to buy cancer diagnostics outfit Personalis ( PSNL) for $1.5 billion on Monday. But shares of both medtech companies skidded.

The deal follows a rumor last week that Merck ( MRK) and others, including potentially Tempus AI, had expressed interest in buying Personalis. Personalis makes a blood test called NeXT Personal that screens for circulating tumor DNA, a marker that a patient's cancer has returned. Tempus already owned 12.5% of Personalis stock.

↑X

Biotech's Next Boom? Inside The Multibillion Dollar Cancer Detection Market

See All Videos

NOW PLAYINGBiotech's Next Boom? Inside The Multibillion Dollar Cancer Detection Market

"We believe this transaction represents an exciting next chapter for Personalis," the company's Chief Executive Chris Hall, said in a written statement. "Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners."

However, at the close, Personalis stock slumped 13.3% to 13.34, while Tempus AI shares took a 7.7% tumble to 48.41.

Tempus' Personalis Bid

Tempus' bid values Personalis shares at $16.25 a share. That equates to roughly a 6% premium to the closing price on Friday and a 28% premium to the 30-day price.

Additionally, Needham analyst Mike Matson says the valuation — 15.5x 2027 enterprise value/sales multiple — is well above typical 3.9x valuation for small- and midcap growth companies.

"We believe the premium is warranted given the strong growth in NeXT Personal (and) multiple Medicare reimbursement wins," Matson said in a client note. He added that there is potentially a "large addressable minimal residual disease market (MRD) of ~$20B" for the combined companies.

The companies expect the deal to close in late 2026 or early 2027, barring any competing bids or potential antitrust concerns. But Matson notes Tempus AI has a limited exposure to the MRD market.

"We believe that TEM is the most logical acquirer of PSNL, and we believe they are paying a fair price," he said.

With the announcement, Personalis also guided to $22.4 million in second-quarter sales. That is above Street expectations for $16.8 million. The company also expects to report 33% sequential growth in test volume.